Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT03628612
Enrolling by invitation Phase 2

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612 · tracked via the Priya Life Science UK tracker
Sponsor
Autolus Limited
Phase
Phase 2
Started
2018-08-02
Last updated
2026-09-22

Condition(s) studied

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell TherapyMultiple MyelomaDLBCLALL, Adult and PediatricT Cell Lymphoma

Investigational drug(s) / intervention(s)

AUTO CAR T cell therapy

AUTO CAR T cell therapy: No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.

Study summary

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Eligibility

Sex
ALL
Min age
1 Year
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients must have received an AUTO CAR T cell therapy on a clinical treatment study. 2. Patients must have provided informed consent for long-term follow-up study prior to participation. 3. Patients must be able to comply with the study requirements. Exclusion Criteria: 1. There are no specific exclusion criteria for this study.

Primary outcome measure(s)

  • Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy — For up to 15 years
    Monitoring of all SAEs / AESIs, including any new malignancy or new diagnosis of neurologic disorders, or other hematologic disorder, related to AUTO CAR T cell therapy. Monitoring of all adverse events of special interest related to AUTO CAR T cell therapy infusion.

Trial sites (9)

FacilityCityRegionStatus
University of Miami Miami Florida
Washington University in St. Louis St Louis Missouri
St David's South Austin Medical Center Austin Texas
Hospital Vall d'Hebron Barcelona Catalonia
Queen Elizabeth University Hospital Glasgow United Kingdom
University College London Hospitals NHS Foundation Trust London United Kingdom
Manchester Royal Infirmary Hospital Manchester United Kingdom
Royal Manchester Children's Hospital Manchester United Kingdom
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne United Kingdom

More Autolus Limited trials in the UK

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis Recruiting
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus Active, not recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) Active, not recruiting

Other trials for the same condition

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma Active, not recruiting
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03628612 on ClinicalTrials.gov ↗ ← All trials in the UK